GAITHERSBURG

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 9, 2024
FDA, Investment, Connective tissue, Food, Research, Diabetes, Weight loss, Attention, Obesity, Three Months, Fibrosis, Webcast

GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024
    Webcast to be held today, May 9, 2024, at 8:30 am ET
    GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • With these promising data, we are preparing for our End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which is expected to occur late in the third quarter.
  • Financial Results for the Three Months Ended March 31, 2024
    Altimmune had cash, cash equivalents and short-term investments totaling $182.1 million at March 31, 2024.
  • Research and development expenses were $21.5 million for the three months ended March 31, 2024, compared to $17.2 million in the same period in 2023.

Ethernet and VoIP Test Solution for High-Speed Network Monitoring and Analytics

Retrieved on: 
Wednesday, May 8, 2024
Sequence, Transfer, QOS, N10, Internet Protocol version 4, LAN, KPI, IP, RTP, SCTP, Filter, GTP, TCP, VXLAN, GRE, IPv6, Class, Computer, Voice over IP, Gigabit Ethernet, N13, Interior, N12, HD, Inner–outer directions, Data-rate units, Wireless, Quality of service, Mobile phone

With PacketScan™ HD, network engineers and cyber security professionals can accurately assess their network performance, identify bottlenecks, troubleshoot infrastructure and applications, and investigate security incidents.

Key Points: 
  • With PacketScan™ HD, network engineers and cyber security professionals can accurately assess their network performance, identify bottlenecks, troubleshoot infrastructure and applications, and investigate security incidents.
  • Vijay Kulkarni, CEO of GL Communications, states, “GL’s PacketScan™ HD is an Ethernet monitoring device designed for high-density network analysis.
  • Equipped with specialized network interface cards, ample storage capacity, and advanced protocol analysis software, it captures and decodes all Voice over IP (VoIP) and Wireless protocols over IP.
  • TCP Analytics is an optional feature with the PacketScan™ HD - Network Monitoring Appliance.

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 8, 2024
Corporate headquarters, FDA, Multiple myeloma, Safety, Risk, Pharmacokinetics, Food, Research, Orphan, Cell, CGMP, Autoimmune disease, Patient, Gene, Society, Messenger, SLE, Therapy, BCMA, Growth, Pharmaceutical industry

GAITHERSBURG, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and recent corporate updates.

Key Points: 
  • Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG.
  • Dosing of first patient in Phase 2 trial of Descartes-08 in patients with SLE expected in second quarter of 2024.
  • Transitioning Corporate Headquarters to Frederick, Maryland
    In March 2024, the Company announced plans to transition its corporate headquarters to Frederick, Maryland.
  • General and administrative expenses were $9.5 million for the quarter ended March 31, 2024, compared to $5.7 million for the quarter ended March 31, 2023.

Altimmune to Participate at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 7, 2024
Conference, Fireside chats, Flour

GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

Key Points: 
  • GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
    JMP Life Sciences Conference (New York, NY)
    Fireside Chat at 9:00 a.m. Eastern Time
    Fireside Chat at 10:00 a.m. Eastern Time
    The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

Altimmune Statement on the Passing of Dr. Stephen Harrison

Retrieved on: 
Thursday, April 25, 2024
Memory, Patient, Liver disease

GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing.

Key Points: 
  • GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing.
  • Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease.
  • His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease.
  • He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.

Comprehensive Network Surveillance and Optimization

Retrieved on: 
Wednesday, April 24, 2024
SS7, Signal-to-noise ratio, TRAU, SIP, PCAP, IMS, Phonation, ANSI, Quality of service, ITU, Table, Lite, IP, SONET, CDR, MEGACO, Communication, HTML, Human voice, Database, Left, PTT, Signal, TDM, Voice over IP, LTE, MGCP, Malicious caller identification, ETSI, 3GPP, Wireless, Report, SIGTRAN, ISDN, GSM, David Acord, PDF, Quality, Environment, Optics, MAP, CAS, Mobile phone

Customized for IP, Wireless, and TDM networks, this platform provides comprehensive solutions to fulfill your monitoring requirements in any environment.

Key Points: 
  • Customized for IP, Wireless, and TDM networks, this platform provides comprehensive solutions to fulfill your monitoring requirements in any environment.
  • GL's Network Surveillance System (NetSurveyorWeb™) is a web-based tool for monitoring and analyzing networks.
  • With support for multiple protocols and interfaces, NetSurveyorWeb™ enables network operators and service providers to improve network performance, diagnostics, and overall reliability.
  • It works with Delay Measurement tools to analyze captured voice traffic and provide precise one-way delay metrics
    Monitoring Air Traffic (ED-137) Network: Supports Air Traffic Network (ED-137) monitoring.

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

Retrieved on: 
Monday, April 22, 2024
Emergent BioSolutions, EBS, ID, Telephone, Webcast

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.

Key Points: 
  • GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.
  • Participants can access the conference call live via webcast .
  • To participate via telephone, please register in advance at this link .
  • A replay of the call can be accessed from the Investors page of Emergent’s website.

GL Communications Introduces Advanced IP Analytics™ Tool

Retrieved on: 
Thursday, April 11, 2024
QOS, Class, DSCP, Quality, IP address, Networking hardware, Data-rate units, Protocol, HDF5, Quality of service, Mobile phone

GAITHERSBURG, Md., April 11, 2024 (GLOBE NEWSWIRE) -- GL Communications Inc., a global leader in telecom test and measurement solutions, addressed the press regarding their new “ IP Analytics™ ” Tool application designed for analyzing data in IP (Internet Protocol) networks.

Key Points: 
  • GAITHERSBURG, Md., April 11, 2024 (GLOBE NEWSWIRE) -- GL Communications Inc., a global leader in telecom test and measurement solutions, addressed the press regarding their new “ IP Analytics™ ” Tool application designed for analyzing data in IP (Internet Protocol) networks.
  • Vijay Kulkarni, CEO of GL Communications, states, “IP Analytics™ is a powerful addition to GL’s suite of network analysis tools.
  • This tool provides detailed insight into recorded IP traffic captured at high speed.
  • Using PacketScan™ HD system along with FastRecorder™ application, users can capture the traffic and analyze the captured data using GL IP Analytics™ tool.

BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

Retrieved on: 
Tuesday, April 9, 2024
Organization, Conference, Drug discovery, COVID-19, Patient, Research, Artificial intelligence, Classification, Personalized medicine, Medicine, Quantum, Bullfrog, Machine learning, CSO

The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.

Key Points: 
  • The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.
  • Chittenden's presentation will explain how quantum methods have been used to decipher complex disease patterns, including analysis of multi-omics cancer data and classification of severe COVID-19 patients.
  • "The research I will highlight during my presentation is a testament to the synergies between quantum computing and machine learning, offering novel solutions to longstanding challenges in biomedical sciences."
  • The Quantum Computing Symposium is a premier event for professionals in the pharmaceutical industry, highlighting the revolutionary role of quantum technologies across various sectors, including drug discovery and supply chain management.

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Retrieved on: 
Thursday, March 28, 2024
Exercise, CUSIP, Messenger, Security (finance), Therapy

During the meeting, Cartesian stockholders approved the issuance of shares of common stock upon conversion of Cartesian’s Series A Non-Voting Convertible Preferred Stock.

Key Points: 
  • During the meeting, Cartesian stockholders approved the issuance of shares of common stock upon conversion of Cartesian’s Series A Non-Voting Convertible Preferred Stock.
  • In addition, stockholders voted to approve a reverse stock split of Cartesian’s issued and outstanding common stock.
  • The reverse stock split will reduce the number of issued and outstanding shares of the Company’s common stock from approximately 165.5 million shares to approximately 5.5 million shares before the automatic conversion of the Company’s Series A Non-Voting Convertible Preferred Stock into common stock, or approximately 17.8 million shares thereafter.
  • The approximately 166.3 thousand shares of Series A Non-Voting Convertible Preferred Stock that remain subject to beneficial ownership limitations will be convertible into approximately 5.5 million shares of common stock for a total of approximately 23.3 million shares of common stock outstanding once converted.